{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:02Z","timestamp":1792001462319,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1124\/jpet.123.001870","type":"journal-article","created":{"date-parts":[[2024,2,26]],"date-time":"2024-02-26T16:55:13Z","timestamp":1708966513000},"page":"106-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["NCP, a Dual Kappa and Mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties"],"prefix":"10.1016","volume":"389","author":[{"given":"Peng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conrad K.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danni","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadet","family":"Inan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Rawls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyusha P.","family":"Pagare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Andrew","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Poklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Halquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Yuan","family":"Liu-Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.123.001870_bib1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/BF02245071","article-title":"Differential effects of systemically administered nor-binaltorphimine (nor-BNI) on kappa-opioid agonists in the mouse writhing assay","volume":"115","author":"Broadbear","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.001870_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/164_2020_395","article-title":"Biased ligands at the kappa opioid receptor: fine-tuning receptor pharmacology","volume":"271","author":"Brust","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2021_433","article-title":"Fundamentals of the dynorphins\/kappa opioid receptor system: from distribution to signaling and function","volume":"271","author":"Cahill","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib4","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1021\/acschemneuro.0c00407","article-title":"Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects","volume":"11","author":"Cao","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.123.001870_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1476-5381.1968.tb00973.x","article-title":"The abdominal constriction response and its suppression by analgesic drugs in the mouse","volume":"32","author":"Collier","year":"1968","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1124\/jpet.123.001870_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.neuropharm.2007.10.015","article-title":"Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity","volume":"54","author":"Contet","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.001870_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0165-6147(86)90257-9","article-title":"In-vivo studies on kappa opioid receptors","volume":"7","author":"Cowan","year":"1986","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.123.001870_bib8","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","article-title":"Opioid receptors: drivers to addiction?","volume":"19","author":"Darcq","year":"2018","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/jpet.123.001870_bib9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0022-3565(25)28712-2","article-title":"The effect of various neurohumoral modulators on the activity of morphine and the narcotic antagonists in the tail-flick and phenylquinone tests","volume":"175","author":"Dewey","year":"1970","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1124\/jpet.123.001870_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0304-3959(02)00259-2","article-title":"Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis","volume":"101","author":"Eisenach","year":"2003","journal-title":"Pain"},{"key":"10.1124\/jpet.123.001870_bib12","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0024-3205(99)00417-8","article-title":"Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist","volume":"65","author":"Endoh","year":"1999","journal-title":"Life Sci"},{"key":"10.1124\/jpet.123.001870_bib13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejphar.2006.01.048","article-title":"Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit","volume":"534","author":"Feng","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1912770","article-title":"A phase 3 trial of difelikefalin in hemodialysis patients with pruritus","volume":"382","author":"Fishbane","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.123.001870_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1054\/npep.2002.0900","article-title":"Opioid receptor genes inactivated in mice: the highlights","volume":"36","author":"Gav\u00e9riaux-Ruff","year":"2002","journal-title":"Neuropeptides"},{"key":"10.1124\/jpet.123.001870_bib16","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1476-5381.1959.tb00924.x","article-title":"Comparative effects of analgesics on pain threshold, respiratory frequency and gastrointestinal propulsion","volume":"14","author":"Green","year":"1959","journal-title":"Br J Pharmacol Chemother"},{"key":"10.1124\/jpet.123.001870_bib17","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/bph.13809","article-title":"Targeting multiple opioid receptors\u2014improved analgesics with reduced side effects?","volume":"175","author":"G\u00fcnther","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(80)90090-2","article-title":"Pruritus after epidural morphine","volume":"2","author":"Hales","year":"1980","journal-title":"Lancet"},{"key":"10.1124\/jpet.123.001870_bib19","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1476-5381.1987.tb11281.x","article-title":"Differential sensitivity of models of antinociception in the rat, mouse and guinea-pig to mu- and kappa-opioid receptor agonists","volume":"91","author":"Hayes","year":"1987","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/npp.2015.201","article-title":"Ethanol reversal of tolerance to the respiratory depressant effects of morphine","volume":"41","author":"Hill","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.123.001870_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104702","article-title":"Verifying the role of 3-hydroxy of 17-cyclopropylmethyl-4,5\u03b1-epoxy-3,14\u03b2-dihydroxy-6\u03b2-[(4\u2032-pyridyl) carboxamido]morphinan derivatives via their binding affinity and selectivity profiles on opioid receptors","volume":"109","author":"Huang","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1124\/jpet.123.001870_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108860","article-title":"Agonist-promoted kappa opioid receptor (KOR) phosphorylation has behavioral endpoint-dependent and sex-specific effects","volume":"202","author":"Huang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.001870_bib23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0022-3565(24)29586-0","article-title":"Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist","volume":"297","author":"Huang","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120014","article-title":"Chemokine receptor antagonists enhance morphine\u2019s antinociceptive effect but not respiratory depression","volume":"285","author":"Inan","year":"2021","journal-title":"Life Sci"},{"key":"10.1124\/jpet.123.001870_bib25","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/164_2020_420","article-title":"Antipruritic effects of kappa opioid receptor agonists: evidence from rodents to humans","volume":"271","author":"Inan","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib26","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1124\/jpet.118.252890","article-title":"Coadministration of chemokine receptor antagonists with morphine potentiates morphine\u2019s analgesic effect on incisional pain in rats","volume":"367","author":"Inan","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0378-4347(00)81850-2","article-title":"Simultaneous determination of morphine and monoamine transmitters in a single mouse brain","volume":"231","author":"Ishikawa","year":"1982","journal-title":"J Chromatogr A"},{"key":"10.1124\/jpet.123.001870_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.118.255661","article-title":"Preclinical testing of nalfurafine as an opioid-sparing adjuvant that potentiates analgesia by the mu opioid receptor-targeting agonist morphine","volume":"371","author":"Kaski","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0014-2999(96)00961-2","article-title":"Kappa-opioid receptor agonist U50,488H modulates cocaine and morphine self-administration in drug-naive rats and mice","volume":"321","author":"Kuzmin","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib30","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1021\/acschemneuro.2c00526","article-title":"Characterization of a potential KOR\/DOR dual agonist with no apparent abuse liability via a complementary structure-activity relationship study on nalfurafine analogues","volume":"13","author":"Li","year":"2022","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/jpet.123.001870_bib31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/14656566.2020.1849142","article-title":"An evaluation of difelikefalin as a treatment option for moderate-to-severe pruritus in end stage renal disease","volume":"22","author":"Lipman","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"10.1124\/jpet.123.001870_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108324","article-title":"Pharmacological and phosphoproteomic approaches to roles of protein kinase C in kappa opioid receptor-mediated effects in mice","volume":"181","author":"Liu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.001870_bib34","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","article-title":"Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in \u03ba opioid aversion","volume":"44","author":"Liu","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.123.001870_bib35","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1523\/JNEUROSCI.0274-19.2019","article-title":"Kappa opioid receptors drive a tonic aversive component of chronic pain","volume":"39","author":"Liu","year":"2019","journal-title":"J Neurosci"},{"key":"10.1124\/jpet.123.001870_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.964724","article-title":"Signaling underlying kappa opioid receptor-mediated behaviors in rodents","volume":"16","author":"Liu-Chen","year":"2022","journal-title":"Front Neurosci"},{"key":"10.1124\/jpet.123.001870_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0166-2236(88)90093-8","article-title":"Anatomy of CNS opioid receptors","volume":"11","author":"Mansour","year":"1988","journal-title":"Trends Neurosci"},{"key":"10.1124\/jpet.123.001870_bib38","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/164_2020_400","article-title":"Clinical profiles of nalfurafine hydrochloride for the treatment of pruritus patients","volume":"271","author":"Miyamoto","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib39","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/BF00432213","article-title":"Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning","volume":"86","author":"Mucha","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.001870_bib40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0022-3565(25)24719-X","article-title":"Tonic pain perception in the mouse: differential modulation by three receptor-selective opioid agonists","volume":"257","author":"Murray","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0160-5402(88)90078-2","article-title":"Methodological refinements to the mouse paw formalin test. An animal model of tonic pain","volume":"20","author":"Murray","year":"1988","journal-title":"J Pharmacol Methods"},{"key":"10.1124\/jpet.123.001870_bib42","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1037\/a0013088","article-title":"Micro\/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability","volume":"16","author":"Negus","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/jpet.123.001870_bib43","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1021\/acs.jmedchem.2c00087","article-title":"Design, synthesis, and biological evaluation of NAP isosteres: a switch from peripheral to central nervous system acting mu-opioid receptor antagonists","volume":"65","author":"Pagare","year":"2022","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.001870_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0165-6147(98)01169-9","article-title":"mu-Opposing actions of the kappa-opioid receptor","volume":"19","author":"Pan","year":"1998","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.123.001870_bib45","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002826-199619050-00009","article-title":"Analgesic efficacy of enadoline versus placebo or morphine in postsurgical pain","volume":"19","author":"Pande","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1124\/jpet.123.001870_bib46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3727\/107156999819565766","article-title":"Comparison of antinociceptive effects induced by kappa opioid agonists in male and female mice","volume":"4","author":"Patrick","year":"1999","journal-title":"Analgesia (Elmsford N Y)"},{"key":"10.1124\/jpet.123.001870_bib47","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1021\/jm061327z","article-title":"Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors","volume":"50","author":"Peng","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.123.001870_bib48","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science"},{"key":"10.1124\/jpet.123.001870_bib49","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0022-3565(25)24168-4","article-title":"Antagonist effects of nalbuphine in opioid-dependent human volunteers","volume":"248","author":"Preston","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(82)90569-6","article-title":"Morphine-receptor dissociation constant and the stimulus-effect relation for inhibition of gastrointestinal transit in the rat","volume":"79","author":"Raffa","year":"1982","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib51","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00192549","article-title":"The cardiovascular and central nervous system effects in the human of U-62066E. A selective opioid receptor agonist","volume":"46","author":"Rimoy","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.bbr.2014.01.003","article-title":"Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females","volume":"262","author":"Robles","year":"2014","journal-title":"Behav Brain Res"},{"key":"10.1124\/jpet.123.001870_bib53","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0376-8716(85)90066-3","article-title":"Nalbuphine","volume":"14","author":"Schmidt","year":"1985","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.123.001870_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40265-021-01472-7","article-title":"Pain management in chronic pancreatitis: summary of clinical practice, current challenges and potential contribution of the M-ANNHEIM classification","volume":"81","author":"Schneider","year":"2021","journal-title":"Drugs"},{"key":"10.1124\/jpet.123.001870_bib55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/5706","article-title":"Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1","volume":"2","author":"Schuller","year":"1999","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.123.001870_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.06.006","article-title":"Effectiveness and selectivity of a heroin conjugate vaccine to attenuate heroin, 6-acetylmorphine, and morphine antinociception in rats: comparison with naltrexone","volume":"204","author":"Schwienteck","year":"2019","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.123.001870_bib57","first-page":"563","article-title":"Differential effects of mu and kappa opioid systems on motivational processes","volume":"75","author":"Shippenberg","year":"1986","journal-title":"NIDA Res Monogr"},{"key":"10.1124\/jpet.123.001870_bib58","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2003.09.057","article-title":"Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions","volume":"995","author":"Suzuki","year":"2004","journal-title":"Brain Res"},{"key":"10.1124\/jpet.123.001870_bib59","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.drugalcdep.2006.01.013","article-title":"Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats","volume":"84","author":"Tao","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.123.001870_bib60","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","article-title":"Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats","volume":"234","author":"Townsend","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.001870_bib61","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/s41386-019-0356-1","article-title":"Sex differences in opioid reinforcement under a fentanyl vs. food choice procedure in rats","volume":"44","author":"Townsend","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/jpet.123.001870_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneumeth.2021.109110","article-title":"A drug-vs-food \u201cchoice\u201d self-administration procedure in rats to investigate pharmacological and environmental mechanisms of substance use disorders","volume":"354","author":"Townsend","year":"2021","journal-title":"J Neurosci Methods"},{"key":"10.1124\/jpet.123.001870_bib63","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/S0024-3205(01)00957-2","article-title":"The novel kappa-opioid receptor agonist TRK-820 suppresses the rewarding and locomotor-enhancing effects of morphine in mice","volume":"68","author":"Tsuji","year":"2001","journal-title":"Life Sci"},{"key":"10.1124\/jpet.123.001870_bib64","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1476-5381.1980.tb07041.x","article-title":"A classification of opiate receptors that mediate antinociception in animals","volume":"69","author":"Tyers","year":"1980","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib65","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0022-3565(25)33422-1","article-title":"U-50,488: a selective and structurally novel non-mu (kappa) opioid agonist","volume":"224","author":"Vonvoigtlander","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib66","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4155\/fmc-2020-0308","article-title":"Exploring the putative mechanism of allosteric modulations by mixed-action kappa\/mu opioid receptor bitopic modulators","volume":"13","author":"Wang","year":"2021","journal-title":"Future Med Chem"},{"key":"10.1124\/jpet.123.001870_bib67","article-title":"Antinociceptive and antipruritic effects of HSK21542, a peripherally restricted kappa opioid receptor agonist, in animal models of pain and itch","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib68","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/jpet.104.073668","article-title":"Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo","volume":"312","author":"Wang","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib69","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0022-3565(25)32972-1","article-title":"Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine","volume":"220","author":"Ward","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib70","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.123.001870_bib71","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.drugalcdep.2013.08.021","article-title":"L-isocorypalmine reduces behavioral sensitization and rewarding effects of cocaine in mice by acting on dopamine receptors","volume":"133","author":"Xu","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.123.001870_bib72","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","article-title":"Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys","volume":"237","author":"Zamarripa","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.123.001870_bib73","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/FBP.0000000000000581","article-title":"The kappa-opioid receptor agonist, nalfurafine, blocks acquisition of oxycodone self-administration and oxycodone\u2019s conditioned rewarding effects in male rats","volume":"31","author":"Zamarripa","year":"2020","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.123.001870_bib74","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1073\/pnas.0406030102","article-title":"A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.123.001870_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108244","article-title":"Nalfurafine modulates the reinforcing effects of oxycodone in male and female adolescent C57BL\/6J mice","volume":"176","author":"Zhang","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.123.001870_bib76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/164_2021_443","article-title":"Preclinical studies on nalfurafine (TRK-820), a clinically used KOR agonist","volume":"271","author":"Zhou","year":"2022","journal-title":"Handb Exp Pharmacol"}],"updated-by":[{"DOI":"10.1124\/jpet.123.001870err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000}}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524172308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.123.001870","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:18:22Z","timestamp":1739960302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524172308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0022356524172308"],"URL":"https:\/\/doi.org\/10.1124\/jpet.123.001870","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NCP, a Dual Kappa and Mu Opioid Receptor Agonist, Is a Potent Analgesic Against Inflammatory Pain without Reinforcing or Aversive Properties","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.123.001870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}